These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38735683)

  • 41. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
    Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
    Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Li P; Liu Y; Liang Y; Bo J; Gao S; Hu Y; Hu Y; Huang H; Huang X; Jing H; Ke X; Li J; Li Y; Liu Q; Lu P; Mei H; Niu T; Song Y; Song Y; Su L; Tu S; Wang J; Wu D; Wang Z; Xu K; Ying Z; Yang Q; Zhang Y; Shi F; Zhang B; Zhang H; Zhang X; Zhao M; Zhao W; Zhao X; Huang L; Zhu J; Qian W; Han W; Liang A
    Cancer Biol Med; 2023 Mar; 20(2):129-46. PubMed ID: 36861439
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recapitulated Late-Onset Inflammatory Toxicities and Progressive Dysautonomia with Persistence of Central Memory CD4+ Chimeric Antigen Receptor T Cells in a Case of Transformed Follicular Lymphoma: Case Report.
    Nishimoto M; Takakuwa T; Kuno M; Makuuchi Y; Okamura H; Nakashima Y; Koh H; Namba H; Itoh Y; Hino M; Nakamae H
    Acta Haematol; 2023; 146(4):338-342. PubMed ID: 37088083
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
    Gauthier J; Bezerra ED; Hirayama AV; Fiorenza S; Sheih A; Chou CK; Kimble EL; Pender BS; Hawkins RM; Vakil A; Phi TD; Steinmetz RN; Jamieson AW; Bar M; Cassaday RD; Chapuis AG; Cowan AJ; Green DJ; Kiem HP; Milano F; Shadman M; Till BG; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2021 Jan; 137(3):323-335. PubMed ID: 32967009
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
    Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
    Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30
    Grover NS; Hucks G; Riches ML; Ivanova A; Moore DT; Shea TC; Seegars MB; Armistead PM; Kasow KA; Beaven AW; Dittus C; Coghill JM; Jamieson KJ; Vincent BG; Wood WA; Cheng C; Morrison JK; West J; Cavallo T; Dotti G; Serody JS; Savoldo B
    Lancet Haematol; 2024 May; 11(5):e358-e367. PubMed ID: 38555923
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Makita S; Yoshimura K; Tobinai K
    Cancer Sci; 2017 Jun; 108(6):1109-1118. PubMed ID: 28301076
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.
    Little JS; Aleissa MM; Beluch K; Gonzalez-Bocco IH; Marty FM; Manne-Goehler J; Koo S; Hammond SP; Jacobson CA
    Blood Adv; 2022 Aug; 6(16):4821-4830. PubMed ID: 35802461
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
    Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
    Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
    Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Palomba ML; Halton E; Bernal Y; van Leeuwen DG; Sadelain M; Park JH; Brentjens RJ
    JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938714
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preliminary Report of the Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical Application.
    Erdoğan E; Yalçın K; Hemşinlioğlu C; Sezgin A; Seyis U; Kançağı DD; Taştan C; Yurtsever B; Turan RD; Çakırsoy D; Abanuz S; Sır Karakuş G; Elek M; Bekoz HS; Gemici Aİ; Sargın D; Arat M; Ferhanoğlu B; Pekgüç E; Örnek S; Büyüktaş D; Birgen N; Ratip S; Ovalı E
    Turk J Haematol; 2022 Aug; 39(3):206-210. PubMed ID: 35848614
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin's lymphoma.
    Frame DG; Geer M; Kasha S; Markstrom D; Scappaticci G; Feeney T; Hayduk A; Mansoor HM; Oberfeld A; D'Antonio H; Anand S; Choi SW; Maciejewski J; Pawarode A; Riwes MM; Tewari M; Magenau J; Ghosh M
    Front Immunol; 2024; 15():1403145. PubMed ID: 38947326
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis.
    Wang N; Meng Y; Wu Y; He J; Liu F
    Immunotherapy; 2021 Mar; 13(4):345-357. PubMed ID: 33406914
    [No Abstract]   [Full Text] [Related]  

  • 54. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.
    Wood AC; Perez AP; Arciola B; Patel K; Johnson G; DiMaggio E; Bachmeier CA; Reid K; Carallo S; Vargas MH; Faramand R; Chavez JC; Shah B; Gaballa S; Khimani F; Elmariah H; Nishihori T; Lazaryan A; Freeman C; Davila ML; Locke FL; Mhaskar R; Bassil C; Jain MD
    Transplant Cell Ther; 2022 Dec; 28(12):829.e1-829.e8. PubMed ID: 36174934
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma.
    Cortes-Bullich A; Perez A; Bachmeier C; Mhaskar R; Chavez JC; Shah B; Nishihori T; Khimani F; Lazaryan A; Davila ML; Locke FL; Jain MD
    Transplant Cell Ther; 2021 Sep; 27(9):768.e1-768.e6. PubMed ID: 34077811
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis.
    Zhou H; Luo Y; Zhu S; Wang X; Zhao Y; Ou X; Zhang T; Ma X
    BMC Cancer; 2018 Sep; 18(1):929. PubMed ID: 30257649
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL.
    Rossi J; Paczkowski P; Shen YW; Morse K; Flynn B; Kaiser A; Ng C; Gallatin K; Cain T; Fan R; Mackay S; Heath JR; Rosenberg SA; Kochenderfer JN; Zhou J; Bot A
    Blood; 2018 Aug; 132(8):804-814. PubMed ID: 29895668
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
    Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
    J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A safe and potent anti-CD19 CAR T cell therapy.
    Ying Z; Huang XF; Xiang X; Liu Y; Kang X; Song Y; Guo X; Liu H; Ding N; Zhang T; Duan P; Lin Y; Zheng W; Wang X; Lin N; Tu M; Xie Y; Zhang C; Liu W; Deng L; Gao S; Ping L; Wang X; Zhou N; Zhang J; Wang Y; Lin S; Mamuti M; Yu X; Fang L; Wang S; Song H; Wang G; Jones L; Zhu J; Chen SY
    Nat Med; 2019 Jun; 25(6):947-953. PubMed ID: 31011207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.